T. Rowe Price Associates
CRBP icon

T. Rowe Price Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

T. Rowe Price Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Buy
26,271
+13,699
+109% +$130K ﹤0.01% 2932
2026
Q1 		$119K Hold
12,572
– – ﹤0.01% 2959
2025
Q4 		$103K Hold
12,572
– – ﹤0.01% 2941
2025
Q3 		$160K Buy
+12,572
New +$120K ﹤0.01% 2835
2025
Q1 		– Sell
-164,735
Closed -$1.95M – 3050
2024
Q4 		$1.95M Sell
164,735
-160,933
-49% -$2.7M ﹤0.01% 1663
2024
Q3 		$6.72M Buy
325,668
+23,482
+8% +$1.2M ﹤0.01% 1222
2024
Q2 		$13.7M Buy
302,186
+109,691
+57% +$4.61M ﹤0.01% 1049
2024
Q1 		$7.55M Buy
+192,495
New +$4.75M ﹤0.01% 1152
2023
Q1 		– Sell
-1,877
Closed -$6K – 2931
2022
Q4 		$6K Hold
1,877
– – ﹤0.01% 2912
2022
Q3 		$10K Hold
1,877
– – ﹤0.01% 2934
2022
Q2 		$14K Buy
1,877
+330
+21% +$3.19K ﹤0.01% 2940
2022
Q1 		$25K Buy
1,547
+553
+56% +$7.33K ﹤0.01% 2955
2021
Q4 		$18K Buy
994
+47
+5% +$1.27K ﹤0.01% 2964
2021
Q3 		$29K Hold
947
– – ﹤0.01% 2923
2021
Q2 		$52K Buy
947
+566
+149% +$31.4K ﹤0.01% 2897
2021
Q1 		$23K Buy
381
+19
+5% +$1.25K ﹤0.01% 2837
2020
Q4 		$14K Sell
362
-3,456
-91% -$129K ﹤0.01% 2660
2020
Q3 		$206K Hold
3,818
– – ﹤0.01% 2411
2020
Q2 		$961K Buy
3,818
+26
+0.7% +$5.25K ﹤0.01% 1799
2020
Q1 		$596K Buy
3,792
+97
+3% +$16.4K ﹤0.01% 1901
2019
Q4 		$605K Sell
3,695
-162
-4% -$23.9K ﹤0.01% 2088
2019
Q3 		$563K Buy
3,857
+663
+21% +$115K ﹤0.01% 2048
2019
Q2 		$664K Buy
3,194
+461
+17% +$98.7K ﹤0.01% 2007
2019
Q1 		$570K Sell
2,733
-283
-9% -$62.4K ﹤0.01% 2075
2018
Q4 		$528K Buy
3,016
+613
+26% +$122K ﹤0.01% 2055
2018
Q3 		$544K Buy
2,403
+10
+0.4% +$1.62K ﹤0.01% 2120
2018
Q2 		$363K Sell
2,393
-625
-21% -$114K ﹤0.01% 2279
2018
Q1 		$552K Buy
3,018
+757
+33% +$170K ﹤0.01% 2049
2017
Q4 		$482K Buy
2,261
+1,677
+287% +$359K ﹤0.01% 2105
2017
Q3 		$125K Buy
+584
New +$114K ﹤0.01% 2476

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

T. Rowe Price Associates's CRBP Position: Q2 2026 in Review

T. Rowe Price Associates increased its Corbus Pharmaceuticals (CRBP) stake by 109% in Q2 2026, buying an estimated $130K and bringing the position to 26,271 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

T. Rowe Price Associates first reported a position in CRBP in Q3 2017 and has held it in 30 quarters since. The position peaked at $13.7M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • T. Rowe Price Associates held 26,271 shares of Corbus Pharmaceuticals worth $247K as of Q2 2026.
  • T. Rowe Price Associates bought 13,699 Corbus Pharmaceuticals shares in Q2 2026, an estimated $130K.
  • Corbus Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2932 holding.
  • T. Rowe Price Associates first reported a position in Corbus Pharmaceuticals in Q3 2017 and has held it in 30 quarters since.
  • T. Rowe Price Associates's Corbus Pharmaceuticals position peaked at $13.7M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.